@xconomy.com 5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com 5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
@techcrunch.com 7 years ago
Oral arguments for who owns CRISPR-Cas9 starts next month